touchONCOLOGY are joined by Dr Petros Grivas (University of Washington Medicine, Seattle, WAS, USA) to discuss results from Cohort 3 of the TROPHY-U-01 Study: Sacituzumab govitecan (SG) in combination with pembrolizumab in patients with metastatic urothelial cancer who progressed after platinum-based regimens.
- What is the rationale for the combination of immune checkpoint inhibitors and antibody-drug conjugates in metastatic urothelial cancer? (00:15-02:14)
- Could you give us a brief overview of the TROPHY-U-01 study? (02:15-03:34)
- What was the patient population of cohort 3 and what were the efficacy and safety findings? (03:35-07:42)
- What were the conclusions of the investigators? (07:43-09:36)
Speaker Disclosure: Dr Petros Grivas discloses consultancy/advisory board participation for Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Seattle Genetics, Pfizer, Janssen, Exelixis, Roche, Genentech, Dyania Health, Mirati Therapeutics, Infinity Pharmaceuticals, QED Therapeutics, 4D Pharma PLC, Regeneron Pharmaceuticals, Astellas Pharma, Guardant Health, Urogen pharma and Gilead Sciences. Dr Petros Grivas also disclosed research funding from Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Bristol-Myers Squibb, Debiopharm Group, Merck, QED Therapeutics, Kure It Cancer Research, GlaxoSmithKline, Mirati Therapeutics, EMD Serono and G1 Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ASCO Genitourinary Cancers Symposium 2022
Share this Video
Related Videos In Genitourinary Cancer
Neal Shore, AACR 2022: KEYNOTE-992 a Phase 3 Study of Pembrolizumab in Muscle-invasive Bladder Cancer
touchONCOLOGY were delighted to talk with Dr. Neal Shore (GenesisCare; Carolina Urologic Research Center, Myrtle Beach, SC, USA) to discuss the phase 3 study of pembrolizumab plus chemoradiotherapy in the treatment of muscle-invasive bladder cancer. The abstract ‘KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent […]
Kim Chi, ASCO GU22: First Results of the Phase III MAGNITUDE Study
Dr Kim Chi (The University of British Columbia, Vancouver, BC, Canada) summarises the first results of the phase 3 MAGNITUDE (NCT03748641) study of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without homologous recombination repair gene alterations. Abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.012 Questions What is […]
Simon Crabb, ASCO GU22: Final Analysis of the ATLANTIS Rucaparib Arm Assessing PARP Inhibitors for Metastatic Urothelial Carcinoma
touchONCOLOGY were joined by Dr Simon Crabb (Southampton University, UK) to discuss his presentation on the rucaparib arm of the ATLANTIS study, a randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma. Questions What is the rationale for the use of PARP inhibitors in the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!